[Clinical evaluation of S 6472 granule preparation (sustained-release cefaclor) in chronic bronchitis].
S 6472 granule preparation, a sustained-release cefaclor, was orally administered to 20 acutely exacerbated cases of chronic bronchitis at a daily dosage of 750 mg (titer) in 2 divided doses for a duration of 7-15 days and its clinical usefulness was evaluated. Clinical efficacies were good in 17 cases and fair in 3 cases, with a rate of efficacy of 85.0%. Organisms isolated from 13 patients were totalling 14 strains, i.e., 5 strains of Streptococcus pneumoniae, 3 strains of Branhamella catarrhalis, 2 strains of Streptococcus sp., 2 strains of Klebsiella oxytoca, 1 strain of Haemophilus influenzae and 1 strain of Staphylococcus aureus. All these strains, except the strains of Streptococcus sp., disappeared upon the administration of the drug. With regard to the safety, no side effects nor abnormal laboratory test values were encountered.
Hiraga
Y
Y
Department of Respiratory Diseases of Internal Medicine, Sapporo Railway Hospital.
Omichi
M
M
Sasaoka
S
S
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001419:Bacteria / Q000302:isolation & purification; D001991:Bronchitis / Q000188:drug therapy* / Q000382:microbiology; D002433:Cefaclor / Q000008:administration & dosage / Q000627:therapeutic use*; D002506:Cephalexin / Q000031:analogs & derivatives*; D002908:Chronic Disease; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
D003692:Delayed-Action Preparations; D002433:Cefaclor; D002506:Cephalexin